October 20, 2016 by Chain Drug Review
Deutsche Bank Securities, George Hill, Rite Aid, Walgreens, Walgreens Boots Alliance, Walgreens-Rite Aid merger
Business, Featured Articles, Leading Headlines, Retail News
DEERFIELD, Ill., and CAMP HILL, Pa. — Walgreens Boots Alliance (WBA) and Rite Aid Corp. are expanding the time frame for completing their planned $17.2 billion merger deal. WBA and Rite Aid said Thursday that they have extended the end date for the agreement to Jan. 27, 2017, from Oct. 27, 2016, and expect the
October 19, 2016 by CDR Blog and Chain Drug Review
FTC approval, Kroger, Walgreens Boots Alliance, Walgreens-Rite Aid merger
CDR Blog
Apparently, Kroger might not become the enabler for Federal Trade Commission approval of the Walgreens-Rite Aid merger. The New York Post reported late Tuesday that Kroger may be taking a pass on buying Walgreens and/or Rite Aid stores that would need to be divested by Walgreens Boots Alliance to gain FTC clearance for its $17
August 6, 2016 by Jeffrey Woldt and Chain Drug Review
Ahold, Delhaize, Federal Trade Commission, Jeffrey Woldt, Ornella Barra, Rite Aid, Stefano Pessina, Walgreens, Walgreens Boots Alliance, Walgreens-Rite Aid merger, WBA
2016, Featured Articles, Issue 08-08-2016, Issues, Leading Headlines, Opinion
It has been slightly more than nine months since Walgreens Boots Alliance agreed to acquire Rite Aid in a $17.2 billion all-cash transaction. Since that time, speculation about whether the Walgreens-Rite Aid merger will pass muster with the Federal Trade Commission has become a staple of discussion for people involved in community pharmacy and the
February 8, 2016 by Chain Drug Review
Rite Aid, Stefano Pessina, Valeant Pharmaceuticals, Walgreens Boots Alliance, Walgreens-Rite Aid merger
2016, Issue 02-08-2016, Issues, News
NEW YORK — Stefano Pessina likes what he sees after Walgreens Boots Alliance (WBA) finished its first full year as a unified company. WBA’s executive vice chairman and chief executive officer told shareholders at its annual meeting here that the company expects its deal to acquire Rite Aid Corp. and its partnership with Valeant Pharmaceuticals
November 9, 2015 by Geoff Walden and Chain Drug Review
Adam Fein, Alex Gourlay, chain drug retailing, CVS/pharmacy, Drug Channels Institute, George Fairweather, John Standley, Rite Aid, Stefano Pessina, Walgreens, Walgreens Boots Alliance, Walgreens-Rite Aid merger
2015, Issue 11-09-2015, Issues, News
DEERFIELD, Ill. — The consolidation of chain drug retailing climaxed last month with Walgreens Boots Alliance Inc.’s (WBA’s) acquisition of Rite Aid Corp. In the largest outright purchase of a chain in the industry’s history, WBA agreed to acquire Rite Aid for $9 per share, or $17.2 billion, including debt. The price represents a premium
November 9, 2015 by Geoff Walden and Chain Drug Review
Adam Fein, Amy Klobuchar, B. Douglas Hoey, Drug Channels Institute, Federal Trade Commission, Mike Lee, National Community Pharmacists Association, Rite Aid, Walgreens Boots Alliance, Walgreens-Rite Aid merger
2015, Issue 11-09-2015, Issues, News
DEERFIELD, Ill. — Walgreens Boots Alliance may have to divest up to 400 of the Rite Aid stores it is acquiring to satisfy antitrust regulations, analysts said. WBA is not publicly speculating on how many units it will have to shutter, said chief executive officer Stefano Pessina. “We have analyzed things very carefully,” he said
November 3, 2015 by Chain Drug Review
Rite Aid, Walgreens, Walgreens Boots Alliance, Walgreens-Rite Aid merger
CDR Blog
By the numbers at least, a look at the map gives some idea of where Rite Aid will help fill out Walgreens’ national store network, if the blockbuster deal by Walgreens Boots Alliance (WBA) to acquire the Camp Hill, Pa.-based drug chain goes through. Walgreens, which already has stores in all 50 states, has said